Table 3 Compliance of practice patterns with FSC marketing conditions for prescription according to prior ICS intake, irrespective of FEV 1 availability
Patients with prior ICS | ICS-naïve patients | |||
|---|---|---|---|---|
GPs (n = 159) | Pulmonologists (n = 120) | GPs (n = 193) | Pulmonologists (n = 238) | |
Approved prescription condition respected, N (%) | ||||
FEV1 < 60% predicted1 | 53 (33.3%) | 76 (63.3%) | 28 (14.5%) | 144 (60.5%) |
History of repeated exacerbations | 109 (68.6%) | 51 (42.5%) | 113 (58.5%) | 55 (23.1%) |
Continuous bronchodilator therapy | 101 (63.5%) | 97 (80.8%) | 57 (29.5%) | 89 (37.4%) |
All conditions respected (regulatory approval criteria) | 25 (15.7%) | 31 (25.8%) | 6 (3.1%) | 16 (6.7%) |
Details of conditions respected, N (%) | ||||
None | 15 (9.4%) | 6 (5.0%) | 53 (27.5%) | 47 (19.7%) |
FEV1 only | 5 (3.1%) | 5 (4.2%) | 9 (4.7%) | 69 (29.0%) |
Repeated exacerbations only | 27 (17.0%) | 2 (1.7%) | 66 (34.2%) | 13 (5.5%) |
Continuous bronchodilator only | 18 (11.3%) | 28 (23.3%) | 13 (6.7%) | 28 (11.8%) |
FEV1 and repeated exacerbations only | 11 (6.9%) | 10 (8.3%) | 8 (4.1%) | 20 (8.4%) |
FEV1 and bronchodilators only | 12 (7.5%) | 30 (25.0%) | 5 (2.6%) | 39 (16.4%) |
Repeated exacerbations and bronchodilators only | 46 (28.9%) | 8 (6.7%) | 33 (17.1%) | 6 (2.5%) |
FEV1 and repeated exacerbations +/− bronchodilators | 36 (22.6%) | 41 (34.2%) | 14 (7.3%) | 36 (15.1%) |
FEV1 or repeated exacerbations | 126 (79.2%) | 86 (71.7%) | 127 (65.8%) | 163 (68.5%) |
N conditions respected, N (%) | ||||
At least one | 144 (90.6%) | 114 (95.0%) | 140 (72.5%) | 191 (80.3%) |
At least two | 94 (59.1%) | 79 (65.8%) | 52 (26.9%) | 81 (34.0%) |